Galderma Group AG (GALD.SW) stock: key figures, P/E, revenue and dividend

Switzerland · ISIN CH1335392721

Price
207.89 CHF
Market cap
49.24 bn CHF
P/E (2025)
76.62
P/S (2025)
9.39
Dividend yield
0.20 %
Net margin
12.24 %
Return on equity (ROE)
7.88 %
Return on assets (ROA)
4.79 %

Galderma Group AG financials

Fiscal year20242025
Revenue4.89 bn USD5.24 bn USD
Gross profit3.40 bn USD3.61 bn USD
EBIT710.00 m USD875.79 m USD
Net income254.00 m USD641.83 m USD
Diluted EPS – continuing operations1.07 USD2.71 USD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.

Galderma Group AG stock (GALD.SW): P/E, revenue, dividend | finmetric